News
Clarametyx to Present on Its Anti-Biofilm Technology Platform During Antimicrobial Pipeline Session At IDWeek 2024
Clarametyx to Present on Its Anti-Biofilm Technology Platform During…
Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory Boards
Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and…
Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline Momentum
Steve St. Onge, PharmD, MBA appointed Senior Vice President of Corporate…
Clarametyx Biosciences Announces $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections
Newly established relationship with Cystic Fibrosis Foundation enables…
Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody Therapy
COLUMBUS, Ohio – June 1, 2023 – Clarametyx Biosciences, Inc. (“Clarametyx”), a…
Clarametyx Biosciences Announces Changes to Its Scientific Advisory Board
Renowned vaccine R&D expert Dr. Jeffrey Almond joins to advise on…
Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial Pneumonia
COLUMBUS, Ohio – November 30, 2022 – Clarametyx Biosciences Inc.…
Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101
COLUMBUS, Ohio – October 5, 2022 – Clarametyx Biosciences Inc. (“Clarametyx”),…
CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial Infections
Supplemental award extends CARB-X collaboration as the Company advances toward…
Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-spectrum Vaccine Technology for Bacterial Infections
Technology prevents development of bacterial biofilms to allow for rapid…
